Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Here's Exactly How Many ETF Shares You'd Need to Replace Your Salary With Dividends

Key PointsThe average American currently makes about $65,000 each year.

Calculating the number of exchange-traded fund (ETF) shares required to replace an individual's salary with dividend income is a straightforward process. To illustrate, we'll use the median American salary of $65,000 as a baseline. The formula is simple: divide the desired income target by the fund's current yield, then divide that result by the current share price. This calculation reveals the total number of shares an individual would need to own to achieve their salary replacement goal through dividends alone.

For a more tangible understanding, let's apply this formula to two of the most popular dividend ETFs available: the Vanguard High Dividend Yield ETF (VYM) and the Schwab U.S. Dividend Equity ETF (SCHD). By doing so, we can observe how the yield of each fund influences the number of shares needed. This information is crucial for investors seeking to harness the power of dividend income to subsidize their living expenses.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

Olawale Opayinka reveals how Eko Atlantic financial model was built

Founder and Managing Director of Makaya Consult FZE, Olawale Opayinka, has disclosed that he was brought in as far back as 2011 to develop...

  • Olawale Opayinka founded Makaya Consult FZE in 2011.
  • Actuarial scientist quantified uncertainty for Eko Atlantic model.
  • Nigeria's population growth could double Lagos in 15 years.

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

  • Amgen is a global pharmaceutical giant with operations in 100+ countries
  • Axsome Therapeutics specializes in CNS disorders like depression and narcolepsy
  • Amgen's revenue heavily concentrated in 3 distributors, introducing risk

More from Saturday 29 August →